Drug Repurposing for Rare Disease Treatment Leads to Reduced Risk, Cost, and Development Time
ثبت نشده
چکیده
home to three Research Institutes and 75 companies, acts as an incubator for biotechnology companies with a wide range of research support technology. As Director of the Drug Discovery Platform of PCB, Jordi Quintana oversees novel research and offers services to the pharmaceutical industry and academia. In 2009 Jordi and his team secured funding to investigate a rare disease, amyloidosis. In particular, they set out to study a subset of the disease called familial amyloid polyneuropathy (FAP).
منابع مشابه
Repurposing of drug candidates for treatment of skin cancer
Skin cancers are highly prevalent malignancies that affect millions of people worldwide. These include melanomas and nonmelanoma skin cancers. Melanomas are among the most dangerous cancers, while nonmelanoma skin cancers generally exhibit a more benign clinical pattern; however, they may sometimes be aggressive and metastatic. Melanomas typically appear in body regions exposed to the sun, alt...
متن کاملOpen-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases
Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-...
متن کاملFilling the gap in CNS drug development: evaluation of the role of drug repurposing
Background and objective: Background and objective: Drug repurposing has been considered a cost-effective and reduced-risk strategy for developing new drugs. Little is known and documented regarding the efficiency of repurposing strategies in drug development. The objective of this article is to assess the extent and meaning of this process in the CNS area. Methods: In order to identify repurpo...
متن کاملChallenges and perspective of drug repurposing strategies in early phase clinical trials
Despite significant investments in the development of new agents only 5% of cancer drugs entering Phase I clinical trials are ultimately approved for routine clinical cancer care. Drug repurposing strategies using novel combinations of previously tested anticancer agents could reduce the cost and improve treatment outcomes. At MD Anderson Cancer Center, early phase clinical trials with drug rep...
متن کاملThe relation between end of induction minimal residual disease and different risk factors in patients with acute lymphoblastic leukemia
Background: Malignant disorder with B or T stem cell basis leads to development and continuation of acute lymphoblastic leukemia (ALL) due to aggregation of blast cells in bone marrow. The environmental, genetic, and demographic factors may influence the disease relapse. The objective of this study was to assess the relation between end of induction minimal residual disease and different risk f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010